A functional genomic approach to actionable gene fusions for precision oncology
Open Access
- 11 February 2022
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (6) , eabm2382
Abstract
Fusion genes represent a class of attractive therapeutic targets. Thousands of fusion genes have been identified in patients with cancer, but the functional consequences and therapeutic implications of most of these remain largely unknown. Here, we develop a functional genomic approach that consists of efficient fusion reconstruction and sensitive cell viability and drug response assays. Applying this approach, we characterize ~100 fusion genes detected in patient samples of The Cancer Genome Atlas, revealing a notable fraction of low-frequency fusions with activating effects on tumor growth. Focusing on those in the RTK-RAS pathway, we identify a number of activating fusions that can markedly affect sensitivity to relevant drugs. Last, we propose an integrated, level-of-evidence classification system to prioritize gene fusions systematically. Our study reiterates the urgent clinical need to incorporate similar functional genomic approaches to characterize gene fusions, thereby maximizing the utility of gene fusions for precision oncology.Keywords
This publication has 42 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexityNature Genetics, 2013
- The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastomaJournal of Clinical Investigation, 2013
- Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancerGenome Research, 2012
- Transforming Fusions of FGFR and TACC Genes in Human GlioblastomaScience, 2012
- Proinvasion Metastasis Drivers in Early-Stage Melanoma Are OncogenesCancer Cell, 2011
- Recurrent gene fusions in prostate cancerNature Reviews Cancer, 2008
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Ba/F3 cells and their use in kinase drug discoveryCurrent Opinion in Oncology, 2007
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005